Using a rhabdomyosarcoma patient-derived xenograft to examine precision medicine approaches and model acquired resistance

Patient-Derived Tumor Xenografts: Transforming Clinical Samples into Mouse Models

(2013) D. Siolas et al.   CANCER RESEARCH

Dual Blockade of the PI3K/AKT/mTOR (AZD8055) and RAS/MEK/ERK (AZD6244) Pathways Synergistically Inhibits Rhabdomyosarcoma Cell Growth In Vitro and In Vivo

(2013) J. Renshaw et al.   CLINICAL CANCER RESEARCH

Companion Biomarkers: Paving the Pathway to Personalized Treatment for Cancer

(2013) M. J. Duffy et al.   CLINICAL CHEMISTRY

Simultaneous targeting of insulin-like growth factor-1 receptor and anaplastic lymphoma kinase in embryonal and alveolar rhabdomyosarcoma: A rational choice

(2013) J. Carlijn van Gaal et al.   EUROPEAN JOURNAL OF CANCER

A multi-site feasibility study for personalized medicine in canines with Osteosarcoma

(2013) Noel R Monks et al.   Journal of Translational Medicine

Characterization of Wnt/β-catenin signaling in rhabdomyosarcoma

(2013) Srinivas R Annavarapu et al.   LABORATORY INVESTIGATION

Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance

(2013) Meghna Das Thakur et al.   NATURE

Meeting report: The future of preclinical mouse models in melanoma treatment is now

(2013) Glenn Merlino et al.   Pigment Cell & Melanoma Research

Cancer Pharmacogenomics: Early Promise, But Concerted Effort Needed

(2013) H. L. McLeod   SCIENCE

Gene Expression Classification of Colon Cancer into Molecular Subtypes: Characterization, Validation, and Prognostic Value

(2013) Laetitia Marisa et al.   PLOS MEDICINE

Evolutionary dynamics of cancer in response to targeted combination therapy

(2013) Ivana Bozic et al.   eLife

Personalized management of patients with solid cancers

(2012) Ahmad Awada et al.   CURRENT OPINION IN ONCOLOGY

Genomic characterization of explant tumorgraft models derived from fresh patient tumor tissue

(2012) David J Monsma et al.   Journal of Translational Medicine

Patient-derived tumour xenografts as models for oncology drug development

(2012) John J. Tentler et al.   Nature Reviews Clinical Oncology

FGFR Genetic Alterations Predict for Sensitivity to NVP-BGJ398, a Selective Pan-FGFR Inhibitor

(2012) V. Guagnano et al.   Cancer Discovery

Exploiting the Cancer Genome: Strategies for the Discovery and Clinical Development of Targeted Molecular Therapeutics

(2011) Timothy A. Yap et al.   Annual Review of Pharmacology and Toxicology

Pharmacotherapy for pediatric soft-tissue sarcomas

(2011) Michela Casanova et al.   EXPERT OPINION ON PHARMACOTHERAPY

The paradigm of personalized therapy in oncology

(2011) Giampietro Gasparini et al.   EXPERT OPINION ON THERAPEUTIC TARGETS

A Pilot Clinical Study of Treatment Guided by Personalized Tumorgrafts in Patients with Advanced Cancer

(2011) M. Hidalgo et al.   MOLECULAR CANCER THERAPEUTICS

Tumor grafts derived from women with breast cancer authentically reflect tumor pathology, growth, metastasis and disease outcomes

(2011) Yoko S DeRose et al.   NATURE MEDICINE

Stimulatory effects of the multi-kinase inhibitor sorafenib on human bladder cancer cells

(2010) A Rose et al.   BRITISH JOURNAL OF PHARMACOLOGY

Genome-Wide Identification of PAX3-FKHR Binding Sites in Rhabdomyosarcoma Reveals Candidate Target Genes Important for Development and Cancer

(2010) L. Cao et al.   CANCER RESEARCH

Randomized Phase II Window Trial of Two Schedules of Irinotecan With Vincristine in Patients With First Relapse or Progression of Rhabdomyosarcoma: A Report From the Children's Oncology Group

(2010) Leo Mascarenhas et al.   JOURNAL OF CLINICAL ONCOLOGY

Translating Gene Expression Into Clinical Care: Sarcomas As a Paradigm

(2010) Torsten O. Nielsen et al.   JOURNAL OF CLINICAL ONCOLOGY

Pilot Study Using Molecular Profiling of Patients' Tumors to Find Potential Targets and Select Treatments for Their Refractory Cancers

(2010) Daniel D. Von Hoff et al.   JOURNAL OF CLINICAL ONCOLOGY

Personalizing Cancer Treatment in the Age of Global Genomic Analyses: PALB2 Gene Mutations and the Response to DNA Damaging Agents in Pancreatic Cancer

(2010) M. C. Villarroel et al.   MOLECULAR CANCER THERAPEUTICS

Finding the tumor copycat: Therapy fails, patients don't

(2010) Lee M Ellis et al.   NATURE MEDICINE

DrugBank 3.0: a comprehensive resource for 'Omics' research on drugs

(2010) C. Knox et al.   NUCLEIC ACIDS RESEARCH

Evaluation of cytarabine against Ewing sarcoma xenografts by the pediatric preclinical testing program

(2010) Peter J. Houghton et al.   PEDIATRIC BLOOD & CANCER

Identifying disease-specific genes based on their topological significance in protein networks

(2009) Zoltán Dezső et al.   BMC Systems Biology

Small interfering RNA library screen of human kinases and phosphatases identifies polo-like kinase 1 as a promising new target for the treatment of pediatric rhabdomyosarcomas

(2009) K. Hu et al.   MOLECULAR CANCER THERAPEUTICS

From Human to Mouse and Back: 'Tumorgraft' Models Surge in Popularity

(2008) K. Garber   JNCI-Journal of the National Cancer Institute

Phase II study of intermediate-dose cytarabine in patients with relapsed or refractory Ewing sarcoma: A report from the Children's Oncology Group

(2008) Steven G. DuBois et al.   PEDIATRIC BLOOD & CANCER